Viridian Therapeutics
VRDN
55 hedge funds and large institutions have $460M invested in Viridian Therapeutics in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 22 increasing their positions, 6 reducing their positions, and 3 closing their positions.
567% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 3
267% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 6
167% more funds holding in top 10
Funds holding in top 10: 3 → 8 (+5)
106% more capital invested
Capital invested by funds: $223M → $460M (+$236M)
41% more funds holding
Funds holding: 39 → 55 (+16)
20.85% more ownership
Funds ownership: 86.24% → 107.09% (+21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$34.2M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$23.8M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$20M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$17.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$24.7M |
| 2 |
ABG
Ally Bridge Group
New York
|
-$5.59M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.55M |
| 4 |
MS
Maven Securities
St Helier,
Jersey
|
-$2.2M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$793K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of America
Charlotte,
North Carolina
| $188K | +$174K | +9,341 | +5,399% |
|
52
Wells Fargo
San Francisco,
California
| $9K | +$1.38K | +74 | +18% |
|
|
LGM
53
Logos Global Management
San Francisco,
California
| – | -$24.7M | -1,500,000 | Closed |
|
54
Walleye Trading
New York
| – | -$123K | -7,500 | Closed |
|
55
UBS Group
Zurich,
Switzerland
| – | -$26.6K | -1,430 | -99% |
|
|
RCM
56
RA Capital Management
Boston,
Massachusetts
| – | -$17K | -1,034 | Closed |
|
|
TRCT
57
Tower Research Capital (TRC)
New York
| – | +$19 | +1 | New |
|
VRDN Hedge Fund Activity: Q4 2021 in Review
55 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q4 2021, worth a combined $460M — up 106% from $223M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new VRDN positions and 3 closed out — a net gain of 17 holders — while 22 added to existing stakes and 6 trimmed.
The largest buyer was VR Adviser, adding an estimated $34.2M. The largest seller was Logos Global Management, exiting entirely with an estimated $24.7M sold.
- 55 institutional investors held Viridian Therapeutics (VRDN) as of Q4 2021, up from 39 in Q3 2021.
- Funds reported $460M of Viridian Therapeutics stock for Q4 2021, up 106% quarter-over-quarter.
- 20 funds opened new Viridian Therapeutics positions in Q4 2021 and 3 closed out, a net change of +17 holders.
- The largest Viridian Therapeutics buyer in Q4 2021 was VR Adviser, an estimated $34.2M added.
- The largest Viridian Therapeutics seller in Q4 2021 was Logos Global Management, an estimated $24.7M sold.
Based on aggregated 13F filings for Q4 2021.